Identifying high-risk patients with lung disease related to rheumatoid arthritis
Official title: Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease (MOUNTAIN)
Run by University of Colorado, Denver · NCT06397677 · Data updated 2026-11-12
This study is trying to find out which patients with lung disease related to rheumatoid arthritis are at the highest risk of their condition getting worse.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 450 (estimated) |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 4 sites (San Francisco, California and 3 other locations) |
| Status | Recruiting |
| Started | January 22, 2024 |
| Main results expected | January 2029 |
| Study ends | January 2034 |
| Registry record updated | May 3, 2024 |
| Trial ID | NCT06397677 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with a multidisciplinary diagnosis of RA-ILD based on established criteria.
✕Probably not a fit
Patients who have previously received medication treatment specifically for RA-ILD or those unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD) who are at the highest risk for disease progression. The investigators will collect clinical, radiologic, and biological data, including blood samples and high-resolution CT scans, to analyze potential markers associated with disease progression. Participants will undergo assessments at baseline and follow-up visits every four months for two years, allowing for comprehensive monitoring of their condition.
Why it matters
Potential benefit: If successful, this study could lead to better identification of patients at risk for progressive lung disease, enabling earlier interventions.
How similar studies have gone: Other studies have shown promise in identifying biomarkers and imaging features associated with lung disease progression, suggesting this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Multidisciplinary diagnosis of RA-ILD based on the 2010 American College of Rheumatology criteria * 18 years of age or older Exclusion Criteria: * Prior medication treatment specifically for RA-ILD * Inability to give informed consent * Pregnant women
Where it's running
-
University of California San Francisco
San Francisco, California, United States Recruiting -
University of Colorado Denver
Aurora, Colorado, United States Recruiting -
University of Kansas
Kansas City, Kansas, United States Recruiting -
University of Michigan
Ann Arbor, Michigan, United States Recruiting
Study contacts
- Principal investigator: Joyce S Lee — University of Colorado, Denver
- Study coordinator: Haylie Lengel
- Email: haylie.lengel@cuanschutz.edu
- Phone: 970-376-8303
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Inspiratory muscle training added to pulmonary rehabilitation for people with RA-related interstitial lung disease
This project will test whether adding inspiratory muscle training to standard pulmonary rehabilitation helps people with rheumatoid arthritis-associated interstitial lung disease breathe easier, walk farther, gain muscle strength, feel better psychologically, and change levels of certain long noncoding RNAs.
-
Using lung ultrasound to detect lung disease in rheumatoid arthritis patients
This study is testing if lung ultrasound can help find lung disease in people with rheumatoid arthritis who have certain risk factors, comparing it to the usual chest CT scans.
-
Screening patients with rheumatoid arthritis for lung disease
This study is trying to see if people with rheumatoid arthritis in Hungary have lung problems by using tests and questionnaires to check their lung health.
-
Identifying lung disease risks in rheumatoid arthritis patients
This study is trying to find out how lung disease develops in people with rheumatoid arthritis and what signs can help doctors catch it early.
-
GenAI-assisted RA bone erosion risk and DMARD choice
This study tests whether GenAI-based decision support can help doctors assess rheumatoid arthritis bone erosion risk and pick DMARDs for newly diagnosed inpatients.
-
Telitacicept for primary Sjögren’s with interstitial lung disease
This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.